Here is a chart summarizing the main prescription, off-label, and over-the-counter (OTC) drugs approved or used for ADHD as of September 2025:

Drug Category	Drug Name(s)	Drug Type	FDA Approval Status for ADHD	Notes
Prescription Stimulants	Methylphenidate (Ritalin, Concerta), Amphetamines (Adderall, Vyvanse, Dexedrine)	Stimulant	FDA-approved	First-line treatments that increase dopamine and norepinephrine levels in the brain.
Prescription Non-stimulants	Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay), Viloxazine	Non-stimulant	FDA-approved	Options for patients who do not tolerate stimulants; affect norepinephrine or alpha-2 receptors.
Emerging Prescription Drug	Centanafadine	Non-stimulant (NDSRI)	Under FDA review (Phase 3 trials)	Affects dopamine, norepinephrine, and serotonin; low abuse potential; phase 3 trial positive.
Off-label Drugs	Modafinil (Provigil), Armodafinil (Nuvigil), Bupropion, Tricyclic Antidepressants	Various	Not FDA-approved for ADHD	Used off-label to improve focus and energy; lower abuse potential than stimulants.
Over-the-Counter (OTC)	Caffeine, amino acids, antioxidants, iron, zinc supplements	Supplements	Not FDA-approved for ADHD	May help ease symptoms or complement prescription meds, but not substitute for them.

REMINDER: Not everyone with ADHD needs to take pharmaceuticals.

---

---

Disclaimer: Our content is for educational and informational purposes only and is not a substitute for professional advice. While we strive for accuracy, errors or omissions may occur. Content may be generated with artificial intelligence tools, which can produce inaccuracies. Readers are encouraged to verify information independently. In some situations, the information offered may lead to unintended or negative consequences. THIS CHART HAS NOT BEEN MEDICALLY REVIEWED.

---

About The ADD Resource Center

Evidence-based ADHD, business, career, and life coaching and consultation for individuals, couples, groups, and corporate clients. 
Empowering growth through personalized guidance and strategies. 

Contact Information 
Email: info@addrc.org 
Phone: +1 (646) 205-8080 
Address: 127 West 83rd St., Unit 133, Planetarium Station, New York, NY, 10024-0840 USA 
 

Follow Us: Facebook | “X”  | LinkedIn  | Substack  | ADHD Research and Innovation

Newsletter & Community 

Join our community and subscribe to our newsletter for the latest resources and insights. 
To unsubscribe, email addrc@mail.com with “Unsubscribe” in the subject line. We’ll promptly remove you from our list. 

Harold Meyer 
The ADD Resource Center, Inc. 
Email: HaroldMeyer@addrc.org 

Legal 
Privacy Policy  

Under GDPR and CCPA, you have the right to access, correct, or delete your personal data. Contact us at info@addrc.org for requests or inquiries.  

• © 2025 The ADD Resource Center. All rights reserved.
  Content is for educational purposes only and not a substitute for professional advice.